PDS Biotechnology Co. (NASDAQ:PDSB) Receives $14.25 Consensus Price Target from Analysts

Shares of PDS Biotechnology Co. (NASDAQ:PDSB - Get Free Report) have earned an average rating of "Buy" from the five brokerages that are currently covering the firm, MarketBeat Ratings reports. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $14.25.

Several research analysts have weighed in on the stock. HC Wainwright reissued a "buy" rating and issued a $21.00 price target on shares of PDS Biotechnology in a report on Thursday, October 24th. StockNews.com upgraded PDS Biotechnology from a "sell" rating to a "hold" rating in a research report on Friday. Finally, Alliance Global Partners raised shares of PDS Biotechnology to a "strong-buy" rating in a report on Wednesday, August 21st.

Hedge Funds Weigh In On PDS Biotechnology

Several large investors have recently bought and sold shares of the company. Vontobel Holding Ltd. increased its stake in shares of PDS Biotechnology by 233.3% in the third quarter. Vontobel Holding Ltd. now owns 40,000 shares of the company's stock valued at $153,000 after buying an additional 28,000 shares during the period. Cubist Systematic Strategies LLC acquired a new position in PDS Biotechnology in the 2nd quarter valued at approximately $146,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of PDS Biotechnology during the second quarter valued at $115,000. Squarepoint Ops LLC acquired a new position in shares of PDS Biotechnology during the second quarter worth $120,000. Finally, Blair William & Co. IL lifted its holdings in shares of PDS Biotechnology by 204.4% during the second quarter. Blair William & Co. IL now owns 121,743 shares of the company's stock worth $357,000 after purchasing an additional 81,743 shares during the period. 26.84% of the stock is currently owned by institutional investors.

PDS Biotechnology Stock Performance

Shares of PDSB stock traded up $0.01 during trading on Friday, reaching $3.20. 250,900 shares of the company's stock were exchanged, compared to its average volume of 310,618. The company has a quick ratio of 3.84, a current ratio of 3.84 and a debt-to-equity ratio of 0.45. The stock has a market capitalization of $117.82 million, a PE ratio of -2.62 and a beta of 1.93. PDS Biotechnology has a twelve month low of $2.53 and a twelve month high of $6.85. The firm's fifty day moving average price is $3.24 and its 200-day moving average price is $3.28.

PDS Biotechnology (NASDAQ:PDSB - Get Free Report) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.23) EPS for the quarter, topping analysts' consensus estimates of ($0.31) by $0.08. During the same quarter in the prior year, the firm earned ($0.37) EPS. As a group, sell-side analysts anticipate that PDS Biotechnology will post -1.24 EPS for the current year.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.